Endogenous thioredoxin is required for redox cycling of anthracyclines and p53-dependent apoptosis in cancer cells.
Apoptosis is a major mechanism of cancer cell destruction by chemotherapy and radiotherapy. The anthracycline class of antitumor drugs undergoes redox cycling in living cells producing increased amounts of reactive oxygen species and semiquinone radical, both of which can cause DNA damage, and consequently trigger apoptotic death of cancer cells. We show here that MCF-7 cells overexpressing thioredoxin (Trx) were more apoptotic in response to daunomycin. Trx overexpression in MCF-7 cells increased the generation of superoxide anion (O2*-) in anthracycline-treated cell extracts. Enhanced generation of O2- in response to daunomycin inTrx-overexpressing MCF-7 cells was inhibited by diphenyleneiodonium chloride, a general NADPH reductase inhibitor, demonstrating that Trx provides reducing equivalents to a bioreductive enzyme for redox cycling of daunomycin. Additionally Trx increased p53-DNA binding and expression in response to anthracyclines. MCF-7 cells expressing mutant redox-inactive Trx showed decreased superoxide generation, apoptosis, and p53 protein and DNA binding. In addition, down-regulation of endogenous Trx expression by small interfering RNA resulted in decreased expression of caspase-7 and cleaved poly(ADP-ribose) polymerase expression in response to daunomycin. These results suggest that endogenous Trx is required for anthracycline-mediated apoptosis of breast cancer cells. Taken together, our data demonstrate a novel pro-oxidant and proapoptotic role of Trx in anthracycline-mediated apoptosis in anthracycline chemotherapy.
Ravi
Dashnamoorthy
D
Department of Pathology and Arkansas Cancer Research Center, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, USA.
Muniyappa
Harish
H
Das
Kumuda C
KC
D000838:Anions; D018943:Anthracyclines / Q000494:pharmacology*; D017209:Apoptosis; D015153:Blotting, Western; D045744:Cell Line, Tumor; D003600:Cytosol / Q000378:metabolism; D004247:DNA / Q000737:chemistry; D003630:Daunorubicin / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D015536:Down-Regulation; D004797:Enzyme-Linked Immunosorbent Assay; D005434:Flow Cytometry; D005456:Fluorescent Dyes / Q000494:pharmacology; D005609:Free Radicals; D020868:Gene Silencing; D016158:Genes, p53; D006801:Humans; D020287:In Situ Nick-End Labeling; D009861:Onium Compounds / Q000494:pharmacology; D016877:Oxidants / Q000737:chemistry; D010084:Oxidation-Reduction; D010100:Oxygen / Q000737:chemistry; D011065:Poly(ADP-ribose) Polymerases / Q000378:metabolism; D011485:Protein Binding; D034622:RNA Interference; D017382:Reactive Oxygen Species; D013481:Superoxides / Q000737:chemistry; D013879:Thioredoxins / Q000737:chemistry / Q000378:metabolism*; D013997:Time Factors; D014162:Transfection; D014357:Trypsin / Q000494:pharmacology; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism*
D000838:Anions; D018943:Anthracyclines; D005456:Fluorescent Dyes; D005609:Free Radicals; D009861:Onium Compounds; D016877:Oxidants; D017382:Reactive Oxygen Species; D016159:Tumor Suppressor Protein p53; D013481:Superoxides; D013879:Thioredoxins; C007517:diphenyleneiodonium; D004247:DNA; D011065:Poly(ADP-ribose) Polymerases; D014357:Trypsin; D010100:Oxygen; D003630:Daunorubicin